Belzutifan Plus Fulvestrant in ER-Positive, HER2-Negative Unresectable Locally Advanced or Metastatic Breast Cancer

What is the Purpose of this Study?

This study focuses on people who have been diagnosed with estrogen receptor-positive (ER+)/HER2-negative breast cancer that cannot be removed surgically, has come back, or has spread to other areas of the body, and/or has grown after receiving hormone-blocking treatments. The purpose of the study is to evaluate the safety and effectiveness of the combination of 2 drugs, belzutifan (an experimental oral medication also known as MK-6482) plus fulvestrant in these patients. Researchers will compare belzutifan plus fulvestrant to everolimus (oral medication approved by the U.S. Food and Drug Administration) plus an endocrine therapy, either exemestane or fulvestrant (selected by the study doctor). Procedures include physical exam, imaging scans, blood and urine sample collection, tumor biopsies and drug administration. Participants will be randomly assigned to 1 of 2 groups. Group 1 will receive belzutifan plus fulvestrant. Group 2 will receive everolimus plus an endocrine therapy (fulvestrant or exemestane).


Eligibility

  • * Has a diagnosis of estrogen receptor positive (ER+)/human epidermal growth factor receptor negative (HER2-) invasive breast carcinoma that is either locally advanced disease not amenable to resection or metastatic disease not treatable with curative intent
  • * Has documented radiographic confirmation of disease progression during or after the last administered endocrine therapy (ET)
  • * Provides additional tissue from the same sample used to determine ER and HER2 status locally
  • * Has received ET in the noncurative setting and has 1) Radiographic disease progression on 12 months or more of ET in combination with CDK4/6 inhibitor in the noncurative setting or 2) Received at least 2 lines of ET in the noncurative setting including CDK4/6 inhibitor where the CDK 4/6 inhibitor was discontinued due to intolerance
Show more

Where can I participate?

  • CS Cancer at Beverly Hills : Nikki Kem-Bernard
  • CS Cancer at Cedars-Sinai Medical Center : Nikki Kem-Bernard


More about this Clinical Trial

What is the full name of this clinical trial?

MK-6482-029: A Phase 2, Randomized, Active-controlled, Open-label, Multicenter Study of Belzutifan Plus Fulvestrant in Participants With Estrogen Receptor Positive, HER2 Negative Unresectable Locally Advanced or Metastatic Breast Cancer After Progression on Previous Endocrine Therapy

Study Details
Disease Type/Condition

Breast

Principal Investigator

Bitar, Jin Sun

Co-Investigators

Alice Chung, Armando Giuliano, Catherine Dang, Farin Amersi, Maryliza El-Masry, Philomena McAndrew, Scott Karlan, Yuan Yuan

Age Group

Adult

Phase

II

IRB Number

STUDY00003784

ClinicalTrials.gov ID

NCT06428396

Key Eligibility
ClinicalTrials.gov

How do I learn more about this study?
Name

Nikki Kem-Bernard

Email
Nikki.Bernard@cshs.org
Study Detail
Disease Type/Condition

Breast

Principal Investigator

Bitar, Jin Sun

Age Group

Adult

Phase

II

IRB Number

MK-6482-029

ClinicalTrials.gov ID

NCT06428396

Key Eligibility
ClinicalTrials.gov

Contact
Name

Nikki Kem-Bernard

Email
Nikki.Bernard@cshs.org